A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Trial details
- Registry ID
- NCT05081167
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Esmethadone HCl; d-Methadone; esmethadone
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)NCT05081167 | RLMD | Phase 3 | Completed | 2022-09-13Actual |
| Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256 | RLMD | Phase 2 | Completed | 2019-07-30Actual |
| Safety of REL-1017 for Major Depressive DisorderNCT04855760 | RLMD | Phase 3 | Completed | 2023-07-27Actual |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04688164 | RLMD | Phase 3 | Completed | 2022-11-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |